NEOMED will set up a Biological Products and Vaccine Centre of Excellence in the Laval facilities of British pharmaceutical company GlaxoSmithKline (GSK), which will invest $47 million in the project over the next five years.
Small and medium-sized companies that move into this new centre can benefit from GSK’s scientific heritage as well as from its research facilities, labs and highly specialized equipment.
“The centre will provide many Québec, Canadian and foreign companies with access to state-of-the-art facilities and remarkable expertise,” says NEOMED President and CEO Max Fehlmann.
In addition, a new contract research organization (CRO) will offer its clinical biology and immunology services to the companies and to GSK for at least three years.
NEOMED was founded in 2012 and contributes greatly to the vitality of Montréal’s biopharmaceutical industry through its innovative R&D business model. Since its founding, the NEOMED Institute has attracted over 20 companies, which have transformed the approach to R&D by fostering partnerships and collaboration.